Germline genomic and phenomic landscape of clonal hematopoiesis in 323,112 individuals

Md Mesbah Uddin^{*1,2}, Zhi Yu^{*1,2}, Joshua S. Weinstock³, Tetsushi Nakao^{1,2,4,5}, Abhishek 3 Niroula^{4,6,7}, Sarah M. Urbut^{1,8}, Satoshi Koyama^{1,2}, Seyedeh M. Zekavat^{1,2,9}, Kaavya Paruchuri^{1,2,10}, 4 Alexander J. Silver¹¹, Taralynn M. Mack¹², Megan Y. Wong^{1,2}, Sara M. Haidermota^{1,2}, Romit 5 Bhattacharya^{1,2,8}, Saman Doroodgar Jorshery¹³⁻¹⁵, Michael A. Raddatz¹¹, Michael C. 6 Honigberg^{1,2,8}, Whitney E. Hornsby¹⁶, Martin Jinye Zhang^{13,17}, Vijay G. Sankaran^{6,18-20}, Gabriel 7 K. Griffin²¹⁻²³, Christopher J. Gibson⁴, Hailey A. Kresge¹¹, Patrick T. Ellinor^{1,2}, Veterans Affairs' 8 Million Veteran Program²⁴, Kelly Cho^{25,26}, Yan V. Sun^{27,28}, Peter W.F. Wilson^{27,29}, Saiju 9 Pyarajan^{25,26}, Giulio Genovese^{13,30,31}, Yaomin Xu^{32,33}, Michael R. Savona¹¹, Alexander P. 10 Reiner^{34,35}, Siddhartha Jaiswal^{36,37}, Benjamin L. Ebert^{4,6,38}, Alexander G. Bick^{#12}, and Pradeep 11 Natarajan#1,2,10 12 13 *Contributed equally to this work 14 [#]Jointly supervised this work 15 Correspondence: alexander.bick@vumc.org (A.G.B.) and pnatarajan@mgh.harvard.edu (P.N.) 16 17 1. Program in Medical and Population Genetics and Cardiovascular Disease Initiative, Broad 18 Institute of Harvard and MIT, Cambridge, MA 02142, USA 19 2. Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts 20 General Hospital, Boston, MA 02114, USA 21 22 3. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA 23 4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA 24 5. Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's 25 26 Hospital, Boston, MA 02115, USA 6. Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA 27 7. Department of Laboratory Medicine, Lund University, Lund, Sweden 28 29 8. Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, 30 MA 02114, USA 9. Computational Biology & Bioinformatics Program, Yale University, New Haven, CT, 31 06510, USA 32 33 10. Department of Medicine, Harvard Medical School, Boston, MA, USA 11. Vanderbilt University School of Medicine, Nashville, TN, USA 34 12. Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical 35 Center, Nashville, TN, USA 36 13. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, 37 Cambridge, MA, USA 38

39	14. Department of Computer Science, University of Toronto, Toronto, Canada
40	15. Department of Computer Science and Electrical Engineering, Massachusetts Institute of
41	Technology, Cambridge, MA, USA
42	16. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
43	17. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA,
44	USA
45	18. Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School,
46	Boston, USA
47	19. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School,
48	Boston, USA
49	20. Harvard Stem Cell Institute, Cambridge, USA
50	21. Department of Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
51	22. Division of Hematopathology, Department of Pathology, Brigham and Women's Hospital,
52	Boston MA 02115, USA
53	23. Epigenomics Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA
54	24. A full list of authors appears in the Supplementary Note
55	25. Veterans Affairs Boston Healthcare System, Boston, MA, USA
56	26. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School,
57	Boston, MA, USA
58	27. Veterans Affairs Atlanta Healthcare Systems, Decatur, Georgia, USA
59	28. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta,
60	Georgia, USA
61	29. Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
62	30. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge,
63	MA 02142, USA
64	31. Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
65	32. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee,
66	USA
67	33. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville,
68	Tennessee, USA
69	34. Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle WA 98109, USA
70	35. Department of Epidemiology, University of Washington, Seattle WA 98195, USA
71	36. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
72	37. Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of
73	Medicine, Stanford, CA, USA
74	38. Howard Hughes Medical Institute, Boston, MA, USA

75 Abstract

76 With age, acquired mutations can cause clonal expansion of hematopoietic stem cells (HSC). This

clonal hematopoiesis of indeterminate potential (CHIP) leads to an increased predisposition to
 numerous diseases including blood cancer and cardiovascular disease. Here, we report multi-

ancestry genome-wide association meta-analyses of CHIP among 323,112 individuals (19.5%

non-European; 5.3% have CHIP). We identify 15 genome-wide significant regions and nominate

81 additional loci through multi-trait analyses, and highlight variants in genes involved in self-

renewal and proliferation of HSC, telomere maintenance, and DNA damage response pathways.

83 We then use Mendelian randomization to establish a causal relationship between CHIP and

84 coronary artery disease. Next, we systematically profile consequences of CHIP across the

phenome, which revealed strong associations with hematopoietic, neoplastic, and circulatory conditions corroborated by polygenic enrichment of CHIP loci in immune cells and

87 cardiomyocytes. These findings expand the genomic and phenomic landscape of CHIP.

89 Introduction

90 Self-renewing cell populations accumulate somatic mutations with aging, although most of these mutations are without functional consequence. In rare cases, these somatic mutations 91 confer a selective advantage leading to clonal expansion¹⁻³. In the case of hematopoietic stem cells, 92 driver mutations in genes with diverse functions, including DNA methylation (DNMT3A, TET2)^{4,5}, 93 RNA splicing $(SF3B1, U2AF1)^6$, chromatin remodeling $(ASXL1)^7$, and DNA damage response 94 95 (TP53, PPM1D)⁸⁻¹⁰ can lead to a clonal expansion of hematopoietic stem cells termed clonal hematopoiesis of indeterminate potential (CHIP) when such mutations make up >4% of peripheral 96 blood cells (variant allele fraction, VAF≥2%). CHIP is the pre-cancerous precursor lesion for 97 myeloid hematologic malignancy¹¹⁻¹³, but numerous studies in human and model systems have 98 linked CHIP to diverse diseases of aging, including coronary artery disease^{14,15}, stroke¹⁶, heart 99 failure¹⁷, chronic obstructive pulmonary disease¹⁸, osteoporosis¹⁹, and chronic liver disease²⁰. 100 However, CHIP is less commonly observed among patients with Alzheimer's disease²¹. 101 Characterizing the germline genetic determinants of CHIP offers the opportunity to prioritize 102 103 unifying features of multiple diseases of aging.

We previously performed a genome-wide association study (GWAS) of CHIP and 104 identified three genomic regions associated with CHIP risk in a study of 3,831 CHIP cases and 105 61,574 controls from whole-genome sequencing of blood DNA utilizing the National Heart, Lung 106 107 and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) study²². This effort identified three germline genetic variants, including one in the TERT promoter, the intronic region 108 of TRIM59, and a distal enhancer of TET2 specific to individuals of African ancestry. These 109 findings enabled further work demonstrating that the low-frequency germline variant at TET2 110 leads to locally altered methylation and decreased germline TET2 expression, subsequently 111 promoting the self-renewal and proliferation of hematopoietic stem cells²². Furthermore, 112 bidirectional Mendelian randomization analyses of leukocyte telomere length (LTL), TERT locus 113 variants, and CHIP highlight the dynamic nature of genomic models across the lifespan²³. 114

Here, we analyze 17,044 CHIP cases and 306,068 controls across four cohorts, including 115 63,442 (19.5%) individuals of non-European ancestry from whole-genome or whole-exome 116 sequencing of blood DNA. Using this expanded dataset, we perform genome-wide discovery 117 analyses and fine-mapping at both variant²⁴ and gene levels²⁵. We identify multiple components 118 of the DNA damage response pathways^{26,27} that lead to CHIP, unifying epidemiological 119 observations regarding enhanced CHIP risk in populations with specific environmental or 120 cvtotoxic exposures^{8,28,29}. Multivariate Bayesian analyses with myeloproliferative neoplasm 121 (MPN)-associated alleles³⁰ further prioritize several additional loci. Finally, we leverage this 122 expanded dataset to systematically profile the disease risk of CHIP compared to another form of 123 clonal hematopoiesis-mosaic chromosomal alterations (mCAs), and further investigate the 124 disease associations by examining cell types³¹ enriched by CHIP (Extended Data Fig. 1). 125

126 **Results**

127 Baseline characteristics

We analyzed 355,183 individuals across four cohorts, UK Biobank (UKB; N=200,128), 128 TOPMed (N=87,116), Vanderbilt BioVU (N=54,583), and Mass General Brigham Biobank 129 (MGBB; N=13,356) for CHIP mutations using previously described methods (see Methods). 130 131 These individuals are of European (N=287,991), African (N=31,900), Asian (N=14,073), Hispanic (N=13,939), and other or unknown (N=7,280) ancestry (Supplementary Table 1). We identified 132 20,302 CHIP mutations in 18,499 individuals (5.2%). Consistent with previous reports²², CHIP 133 was robustly associated with age (Fig. 1a) and had a similar distribution of genes identified in 134 135 prior studies. Across all cohorts, 90.8% of individuals with CHIP driver mutations had only one identified mutation (Fig. 1b). DNMT3A, TET2, and ASXL1 are the most frequent mutated genes, 136 accounting for more than 75% of CHIP mutations (Fig. 1c). Compared with other cohorts, MGBB 137 has a relatively lower proportion of individuals with DNMT3A mutations but a relatively larger 138 139 proportion with TET2 mutations. The next seven most frequent genes are PPM1D, TP53, JAK2, SF3B1, SRSF2, GNB1, and CBL. For most of these top mutated genes, the corresponding VAF for 140 participants in TOPMed are larger than that seen in other cohorts, which is likely explained by 141 technical sensitivities between whole-genome (TOPMed) and whole-exome (UKB and MGBB) 142 sequencing-based CHIP detection. The median VAF of DNMT3A was 0.08 in UKB, 0.13 in 143 144 TOPMed, and 0.09 in MGBB; the median VAF of TET2 was 0.11 in UKB, 0.16 in TOPMed, and 0.09 in MGBB. JAK2 has the largest clonal fraction among the top ten genes, with a median VAF 145 of 0.30 in UKB, 0.21 in TOPMed, and 0.32 in MGBB (Fig. 1d). In BioVU, CHIP was identified 146 in four driver genes, DNMT3A, JAK2, TET2, and ASXL1, using a customized genotyping array 147 148 (see Methods). The most common mutations in BioVU samples were JAK2 V617F and DNMT3A R882C/H. 149

150 Fifteen genome-wide significant loci associated with CHIP categories

We performed multi-ancestry meta-analyses of overall CHIP (pooled sample size, 17,044 151 152 cases, and 306,068 controls), DNMT3A (8,949 cases and 307,971 controls), and TET2 (2,851 cases and 307,527 controls) CHIP GWAS from TOPMed, UKB, MGBB, and BioVU. Here, we 153 performed three GWAS for each of the four participating cohorts, followed by multi-ancestry 154 meta-analyses using the fixed-effects inverse-variance-weighted approach (see Methods). A total 155 of 323,112 participants and 21,455,227 variants (minor allele frequency (MAF)>=0.1%; variants 156 present in >=two studies) remained after variant filtering and quality-control procedures. There 157 was no evidence of artificial inflation of association statistics due to the population structure 158 (genomic control factor $\lambda_{GC} = 1.05$ for CHIP and DNMT3A, 1.06 for TET2; Fig. 2a-c). The SNP 159 heritability (h^2_{SNP}) of overall CHIP among the entire study population was estimated at 3.5% 160 (SD=0.002) on the observed scale and 15.8% (SD=0.011) on the liability scale using the BLD-161 LDAK model (see Methods and Supplementary Table 2), representing a four-fold increase from 162 the previous estimate²². 163

We discovered ten loci associated with overall CHIP at genome-wide significance after 164 correcting for multiple testing ($P < 1.67 \times 10^{-8}$, i.e., $5.0 \times 10^{-8}/3$). Seven of the loci are new and 165 mapped to the following genes based on proximity of the lead variants: PARP1, CD164/SMPD2, 166 ATM, ITPR2, MSI2, SETBP1, and CHEK2 (Fig. 2a and Supplementary Tables 3,4). Consistent 167 168 with previous report²², the strongest signal remained at the *TERT* locus, with rs7705526-A as the lead variant (odds ratio (OR) (95% confidence interval (CI)) = $1.26 (1.23-1.29); P=2.6 \times 10^{-81}$). 169 Regional association plots are shown in Extended Data Fig. 2. The effects of associated SNPs 170 were largely homogeneous across studies (i.e., heterogeneity P>0.05, Supplementary Tables 171 3,4). Summary-statistics-based conditional analysis yielded 12 independent SNPs that reached 172 genome-wide significance at $P < 1.67 \times 10^{-8}$ (Supplementary Table 5). 173

174 CHIP driver gene-specific association analyses identified ten loci associated with 175 *DNMT3A* and six loci associated with *TET2* (Fig. 2bc, Extended Data Fig. 3,4, Supplementary 176 Tables 4, 6-9). *TCL1A* is a newly discovered locus that significantly increased the risk for 177 *DNMT3A* CHIP (rs2887399-T; OR (95% CI) = 1.19 (1.15-1.23); $P=1.26 \times 10^{-22}$) and significantly 178 reduced the risk for *TET2* CHIP (rs4900291-T; OR (95% CI) = 0.78 (0.73-0.84); $P=2.92 \times 10^{-11}$).

179 Interestingly, there was a larger overlap of loci associated with overall CHIP and *DNMT3A* 180 CHIP: nine of the ten loci were common between the two CHIP categories (**Fig. 2d**). CHIP-181 associated loci ($P < 1.67 \times 10^{-8}$) also overlapped with LTL³², expanded mCAs³³, and MPN³⁰ 182 associated genome-wide significant loci ($P < 5 \times 10^{-8}$). Here, seven, five, and three of the CHIP-183 associated loci overlapped with LTL, expanded mCAs, and MPN-associated loci, respectively 184 (**Fig. 2d**).

We also conducted a joint multivariate analysis across MPN³⁰, overall CHIP, *DNMT3A*, and *TET2* using empirical Bayes hierarchical modeling³⁴ (see **Methods**). This approach yielded a 3-fold boost in power for discovery. Compared with conventional GWAS, we identified 39, 39, and 46 more genetic regions for overall CHIP, *DNMT3A*, and *TET2* CHIP, respectively, with evidence for the association through this method (**Extended Data Fig. 5**).

190 Statistical fine-mapping identified causal variants at *ATM* and *PARP1*

Statistical fine-mapping was conducted using the results of the European meta-analysis and 191 LD matrix derived from the UKB European population to identify the causal variants in the 192 193 associated loci (see Methods). We identified 27 variants with posterior inclusion probability (PIP)> 10% (Supplementary Table 10), among which a missense variant, rs1800057-G, in the newly 194 discovered ATM gene (ENST00000675843.1:c.3161C>G:p.Pro1054Arg; OR (95% CI) =1.28 195 (1.18-1.37); $P=1.3 \times 10^{-10}$) showed higher posterior probability of inclusion (PIP 22%) in the locus 196 (Fig. 3a). The risk allele for this coding variant was predicted to be deleterious by various 197 functional annotation tools (Fig. 3b). Decreased function of the ATM gene and increased risk for 198 CHIP aligns with the prior observation that the loss of function and low expression of ATM were 199 associated with tumorigenesis and worse prognosis in various cancers, including MPN^{35,36}. In 200 another newly discovered locus at PARP1, we identified a non-coding variant, rs1527365-T, with 201

high posterior probability (PIP=33%; OR (95% CI) = 0.88 (0.85-0.91); $P=7.0 \times 10^{-13}$), which is 202 the lead variant in European meta-analysis of CHIP GWAS (Fig. 3c). The T allele at rs1527365 is 203 protective for overall CHIP and DNMT3A CHIP (Supplementary Tables 3,6) and associated with 204 decreased expression of PARP1 in whole blood (Fig. 3d; normalized effect size=-0.067, 205 206 $P=1.7 \times 10^{-4}$, GTEx v8). This is consistent with the observations that a higher expression of *PARP1* is a marker for worse clinical outcomes in various tumors, including myeloid leukemia, and that 207 inhibition of *PARP1* has anti-tumor effects³⁷. rs1527365 is also a cis-methylation QTL where the 208 T allele is associated with increased DNA methylation at CpGs around PARP1 (data from 209 GoDMC³⁸:http://mqtldb.godmc.org.uk/), further supporting the negative regulation of *PARP1* by 210 this allele. 211

212 Similarity-based gene prioritization identified several putative causal genes

Next, to prioritize causal genes from the GWAS data, we incorporated a novel gene 213 prioritization method, Polygenic Priority Score (PoPS)²⁵. PoPS combines GWAS data with other 214 omics data (e.g., gene expression, biological pathway, and predicted protein-protein interaction) 215 to prioritize casual genes based on functional similarity. We applied PoPS to summary-level data 216 from the UKB GWAS results of overall CHIP, DNMT3A, and TET2 using European ancestry 217 individuals from the UKB study population as a reference panel. Features from gene expression 218 219 data, protein-protein interaction networks, and pathway membership that passed a marginal feature selection step were included in the final predictive model (see Methods). We identified 26 220 prioritized gene-trait pairs. Top putative causal genes prioritized by PoPS (PoPS score>0.3) 221 included PARP1, ITF80, TET2, TERT, SMPD2, ATM, ITPR2, MSI2, and CHEK2 for overall CHIP 222 223 (Supplementary Table 11), PARP1, ITF80, TERT, SMPD2, ATM, ITPR2, TCL1A, SETBP1, and CHEK2 for DNMT3A CHIP (Supplementary Table 12), and AGTRAP, BDKRB2, and ZFPM1 224 for TET2 CHIP (Supplementary Table 13). This prioritization corroborates with the fine-mapped 225 causal variants at *PARP1*, *TERT*, and *ATM* as well as previously validated causal variants at 226 TET2²² and TCL1A³⁹. Further, the consistency between prioritized genes by PoPS (similarity-227 based approach) and distance (non-similarity-based approach) suggest high confidence²⁵. 228

229 Mendelian randomization refined causality between CHIP and coronary artery 230 disease

Leveraging the large CHIP meta-analysis, we used Mendelian randomization (MR) to 231 understand the causality of CHIP and disease outcomes. Since CHIP has been associated with 232 coronary artery disease (CAD) incidence in humans and atherosclerosis in a Tet2 CHIP mouse 233 234 model^{14,40,41}, we performed MR analyses of overall CHIP, DNMT3A, and TET2 with CAD. While 235 genetic predispositions for CHIP overlapped with those for LTL, previous MR studies support inverse causality for LTL on CAD, implying complex causal relationships between CHIP-LTL, 236 and LTL-CAD²³. Thus, we carefully selected instrumental variables (IVs) to avoid clear violations 237 238 of MR assumptions by excluding IVs 1) associated with known confounders between CHIP and CAD, including hypercholesterolemia, hypertension, type 2 diabetes, body mass index, smoking 239

status, or 2) having more robust associations with LTL than with CAD, and/or 3) having inverse 240 effect sizes for LTL, CHIP, and CAD, accounting for the inverse causal association between LTL 241 and CAD. Mendelian randomization using the robust adjusted profile score (MR-RAPS) was used 242 given the limited power for CHIP analyses due to low heritability, especially the gene-specific 243 244 analyses. MR-RAPS is a novel method that accommodates weak instruments in the MR framework. The approach was used as our primary method, and a liberal p-value threshold was applied for IV 245 selections (see Methods)⁴². Using summary statistics of multi-ancestry meta-analysis for CHIP, 246 we observed significant positive causal effects of genetically-determined TET2 CHIP mutation 247 risk on CAD risk ($P=3.2 \times 10^{-4}$). In contrast, the overall CHIP and DNMT3A CHIP mutation results 248 were null, consistent with differential causal effects on CAD risk by CHIP mutated gene types 249 (Fig. 4). However, sensitivity analyses using other MR approaches that do not allow for weak 250 instruments yielded null results across overall CHIP, DNMT3A, and TET2 CHIP mutations 251 (Extended Data Fig. 6 and Supplemental Tables 14-16). 252

253 Phenome-wide scans yielded different patterns between CHIP and mCAs

The dataset assembled now permits a comprehensive and well-powered phenome-wide association study (PheWAS) of CHIP. At the same time, we contrast CHIP with a different ageassociated clonal hematopoietic phenomenon, mosaic chromosomal alterations (mCAs) (see **Methods**). We not only compared the CHIP and mCAs in the same study population where information on both is available, but we also examined the mCAs in an extended dataset (N= 1,116,579) as a secondary analysis to maximize the discovery power.

260 Among incident hematopoietic and neoplastic conditions (Fig. 5a and Supplementary Table 17), significant associations were observed with leukemias [CHIP: hazard ratio (HR) 261 =1.78, 95% CI 1.42 - 2.24, FDR= 1.76×10^{-4} ; autosomal mCAs: HR=6.87, FDR= 5.81×10^{-89}], 262 with the largest effect for expanded CHIP (i.e., VAF>10%) and myeloid leukemias (HR 11.56, 263 95% CI 6.67 - 20.06, FDR=3.67×10⁻¹⁵) and for expanded autosomal mCAs and lymphoid 264 leukemias (HR 78.36, 95% CI 57.55 - 106.69, FDR=5.91 $\times 10^{-166}$), as shown previously^{2,43}. 265 Besides hematopoietic malignancies, neoplastic associations were also detected with incident 266 respiratory cancer (Expanded CHIP: HR 1.52, 95% CI 1.27 - 1.81, FDR=4.05×10⁻⁴), malignancies 267 of the brain for CHIP (HR=1.84, 95% CI 1.31 - 2.58, FDR=0.025), and skin cancer for mCAs 268 269 (Expanded autosomal mCAs: HR 1.45, 95% CI 1.15 - 1.82, FDR=0.024).

270 For CHIP, across other non-hematopoietic/neoplastic conditions, significant associations were observed with circulatory, gastrointestinal, genitourinary, renal, and infectious conditions, 271 some of which showed consistent associations with mCAs (Fig. 5b and Supplementary Table 272 273 17). In particular, among circulatory conditions, association with incident arterial embolism and thrombosis was detected for expanded TET2 (HR=2.97, 95% CI 1.58 - 5.59, FDR=0.03). While 274 no significant association for mCAs was detected among the same sample set analyzed for CHIP, 275 a significant association with incident arterial embolism and thrombosis was detected for expanded 276 277 mCAs (HR=1.17, 95% CI 1.08 - 1.27, FDR=0.0017) (Supplementary Table 18 and Extended

Data Fig. 7), particularly for expanded ChrX mCAs in females (HR=3.92, 95% CI 1.92 - 8.02, 278 FDR=0.029). Additionally, significant associations with cardiomyopathy for CHIP (HR 1.64, 95% 279 CI 1.30 - 2.07, FDR=0.0026) but not for mCAs were observed (Supplementary Table 18 and 280 Extended Data Fig. 7). The following were other notable CHIP-specific cardiovascular 281 associations: hypertension, pulmonary heart disease, and lower extremity varicose veins. While 282 CHIP was not strongly associated with CAD in the PheWAS analysis, using solely combined ICD-283 9 and ICD-10 codes per the 'phecode' algorithm, further analyses using a more comprehensive 284 CAD phenotype (composite of myocardial infarction, coronary revascularization, stroke, and death) 285 yielded significant associations between CHIP and incident CAD (Supplementary Table 19). 286

Other than circulatory conditions (**Fig. 5b and Supplementary Table 18**), several additional incident phenotypic associations were observed. CHIP-specific associations included peptic ulcer disease and diverticulosis. mCAs and CHIP were similarly associated with acute renal failure and pneumonia, and mCAs had a larger association with splenomegaly. Additionally, mCAs were more strongly associated with sepsis and viral infections, while CHIP was more strongly associated with bacterial infections.

293 Polygenic associations of CHIP at a single-cell level corroborated PheWAS findings

We used scDRS³¹ to assess the polygenic enrichment of the overall CHIP, DNMT3A, and 294 TET2 GWASs in different cell populations in 2 single-cell RNA sequencing (scRNA-seq) data 295 sets, namely the Tabula Muris Senis (TMS) mouse cell atlas⁴⁴ and Tabula Sapiens (TS) human 296 cell atlas⁴⁵. scDRS assesses excess expression of GWAS-associated genes in single-cell data; we 297 considered FDR<0.3 for significant association and P<0.01 for suggestive association (see 298 299 Methods). Results are reported in Figure 6. We determined the polygenic signal in the CHIP GWAS is significantly more highly expressed in ventricular myocytes and atrial myocytes from 300 the heart (P < 0.001, and P = 0.004, respectively) and neuronal stem cells and oligodendrocytes from 301 the brain non-myeloid tissue (P=0.004, and 0.01 respectively). DNMT3A is suggestively more 302 highly expressed in ventricular myocytes from the heart (P=0.003). TET2 is significantly more 303 highly expressed in DN4 thymocytes from the thymus (P=0.002) and suggestively in T cells 304 (P=0.007; combined from trachea, heart, brown adipose tissue, and limb muscle). Notably, the 305 polygenic enrichment findings corroborate our PheWAS results and the existing literature^{14,21}. The 306 307 results are also consistent between TMS and TS (Extended Data Fig. 8a) and between cell type-308 level and tissue-level associations (Extended Data Fig. 8b,c). In addition, we assessed the robustness of the results by subsampling the TMS data and subsampling the putative trait gene 309 sets. We determined that the results are consistent across the subsampling experiments (Extended 310 311 Data Figure 9).

313 **Discussion**

In this large and diverse genetic study of CHIP, we identified ten genome-wide significant regions, including seven that are new and one that is driver gene-specific. We highlight variants in *ATM* and *PARP1* as causal CHIP variants leading to decreased DNA damage repair and a number of putative causal genes. We systematically profiled CHIP consequences phenome-wide and highlighted strong associations with hematopoietic, neoplastic, and circulatory conditions corroborated by the polygenic enrichments of CHIP in immune cells and myocytes. These findings provide an expanded genomic and phenomic landscape for clonal hematopoiesis.

Our study has several important findings. First, the relatively large sample size enabled 321 322 better-powered delineations of potential mechanisms that contribute to CHIP and specific driver 323 genes, including failure to repair DNA damage and differential clonal competitive advantage. Among the newly discovered CHIP-associated genes, ATM has been significantly associated with 324 the JAK2 V617F clonal hematopoiesis and MPNs⁴⁶, and it is a core component of the DNA repair 325 system, and the fine-mapped missense variant on this gene is predicted to decrease its function⁴⁷. 326 Also, high *PARP1* expression has been shown to exacerbate DNA damage⁴⁸, and the fine-mapped 327 regulatory variant, which reduces CHIP risk, decreases PARP1 expression in the human blood 328 cells. Driver gene-specific GWAS showed differential association patterns for DNMT3A and TET2 329 CHIP mutations. In particular, we observed significant signals at the TCL1A locus for both 330 331 DNMT3A and TET2, with the direction of effects being opposite. TCL1A has been observed to implicate in B-cell and T-cell and malignancies^{49,50}, and its encoded protein is thought to promote 332 Akt activity, which is central to many signaling pathways, such as cellular proliferation, growth, 333 and survival^{51,52}. Recent evidence using gene expression data suggested activation of *TCL1A* as an 334 event driving clonal expansion for TET2, but not for DNMT3A³⁹ and our GWAS findings provide 335 further evidence to support that finding. These findings indicate that while driver mutations 336 ultimately yield CHIP, their respective heritable bases have shared and distinct heritable factors. 337

Second, we found that the specific somatic mutation in the hematopoietic stem cell clone 338 was indicative of specific disease consequences. We conducted a phenome-wide scan for overall 339 CHIP and individual driver mutations and contrasted CHIP with a distinct clonal hematopoietic 340 phenomenon, lymphoid-biased mCAs. We observed associations of CHIP and mCAs with clonal 341 hematopoiesis, hematologic malignancy, and non-malignant diseases linked to aging, with 342 leukemia showing the strongest association followed by circulatory, gastrointestinal, genitourinary, 343 renal, and infectious conditions, most of which showed consistent associations between CHIP and 344 mCAs. However, marked heterogeneity was also observed between CHIP and mCAs. For example, 345 unique protective associations for ChrY mCAs and cardiomyopathy in males were observed, while 346 opposing effects between CHIP and mCAs on essential hypertension, pulmonary heart disease, 347 and lower extremity varicose veins were observed. 348

Third, the application of novel statistical methods yielded new insights into CHIP biology. In alignment with the differential pheWAS associations between *DNMT3A* and *TET2* CHIP mutations, our MR analyses demonstrated their differential causal effects on CAD. We observed

a significant causal effect of genetically determined increased risk for acquiring TET2 CHIP 352 mutation on an increased risk for CAD, whereas the causal relationship was null for DNMT3A. 353 Furthermore, our study leveraged a novel statistical approach to access the polygenic enrichment 354 of CHIP, DNMT3A, and TET2 in scRNA-seq data³¹. Corroborating the significant cardiomyopathy 355 356 association in pheWAS results, CHIP had the strongest involvement with ventricular myocytes and atrial myocytes, while DNMT3A and TET2 demonstrated different suggestive association 357 patterns at the cell-type level. Lastly, using an empirical Bayes hierarchical approach for jointly 358 modeling multiple traits³⁴, we leveraged the high correlation between MPN and CHIP variables 359 and nominated three-fold additional genetic regions that contain strong signals for CHIP, 360 DNMT3A, and TET2. 361

Important limitations of our study include that many of the newly analyzed samples are of European ancestry, limiting our ability to benefit from the full diversity of genetic variation present in diverse ancestries. Second, the cross-sectional nature of our CHIP analysis limits conclusions regarding the temporal evolution between CHIP and these diseases. Third, the technical sensitivity of whole genome and whole exome sequencing precludes the ability to evaluate the clinical significance of CHIP mutations at low VAF.

368 Overall, our analyses of the inherited basis of CHIP identified new mechanisms affecting 369 somatic mutation acquisition and clonal fitness with an expanded appreciation for how these 370 somatic mutations shape disease phenotypes.

371

372 Methods

373 Study population

UK Biobank (UKB) is a prospective cohort study of ~500,000 participants (age range 4069 at enrollment) from across the United Kingdom with deep genetic (DNA isolated from blood)
and phenotypic data⁵³. The present study was conducted under UKB application ID 7089 and
50834. Secondary use of these data was approved by the Mass General Brigham Institutional
Review Board (protocol 2021P002228).

TOPMed is a research program generating genomic data from DNA isolated from blood 379 and other -omics data for more than 80 NHLBI-funded research studies with extensive phenotype 380 data^{22,54}. A total of 51 studies with diverse reported ethnicity (40% European, 32% African, 16% 381 Hispanic/Latino, 10% Asian) were included in the Freeze 6 (https://topmed.nhlbi.nih.gov/topmed-382 whole-genome-sequencing-methods-freeze-6). Each of the included studies provided informed 383 consent. Secondary analysis of the TOPMed data was approved by the Mass General Brigham 384 Institutional Review Board (protocol 2016P001308). All relevant ethics committees approved this 385 study, and this work is compliant with all applicable ethical regulations. 386

Mass General Brigham Biobank (MGBB)⁵⁵ is a volunteer biobank of patients receiving care at Mass General Brigham with electronic health records and genetic and phenotypic data on ~50,000 participants (<u>https://biobank.massgeneralbrigham.org/</u>). The present secondary analyses were approved by the Massachusetts General Hospital Institutional Review Board (protocol 2018P001236).

BioVU, the Vanderbilt DNA Databank, is a de-identified biorepository that includes DNA from the peripheral blood remaining from routine clinical testing of approximately 250,000 patients^{56,57}. The present secondary analyses were approved by the Vanderbilt University Medical Center Institutional Review Board (IRB #201783).

396

397

398 CHIP detection

399 *UKB*

400 Whole exome sequencing of whole blood DNA of 200,628 participants was used to identify somatic mutations. We selected 500 random youngest samples for panel-of-normal (PON) and 401 called somatic mutations on the remaining 200,128 samples using Mutect2 software⁵⁸ in the Terra 402 platform (https://portal.firecloud.org/?return=terra#methods/gatk/mutect2-gatk4/20). PON was 403 used to minimize sequencing artifacts, and Genome Aggregation Database (gnomAD)⁵⁹ was used 404 to filter likely germline variants from the putative somatic mutations call set. Each Variant Call 405 Format (VCF) file was annotated using ANNOVAR software⁶⁰, and putative CHIP mutations were 406 identified using the pipeline described in Bick et al.²² (https://app.terra.bio/#workspaces/terra-407 outreach/CHIP-Detection-Mutect2; last accessed Feb 7, 2022). For identifying CHIP, pathogenic 408 variants were queried in 74 genes known to drive clonal hematopoiesis and myeloid malignancies 409 (list of variants queried is presented in Supplementary Table 20)²². We kept variants for further 410 curation if (i) total depth of coverage ≥ 10 , (ii) number of reads supporting the alternate allele ≥ 3 , 411 (iii) ≥ 1 read in both forward and reverse direction supporting the alternate allele, and (iv) 412 VAF 20.02. Finally, CHIP mutations that passed sequence-based filtering were manually curated 413 by a team of hematopathologists. The median depth of coverage was 77 (mean=80; SD=31.2; 414 415 range 9-305), and the median number of supporting reads were 7 (mean=10; SD=8.6; range 3-101) 416 in the final CHIP call set.

417

418 NHLBI TOPMed

Whole-genome sequencing of blood DNA was performed on 97,691 samples from Freeze 8
NHLBI TOPMed data with a mean depth of at least 30× using Illumina HiSeq X Ten instruments.
All sequences in CRAM files were remapped to the hs38DH 1000 Genomes build 38 human
genome reference, following the protocol published previously⁶¹. Single nucleotide

423 polymorphisms (SNP) and short indels were jointly discovered and genotyped across the TOPMed

samples using the GotCloud pipeline 62 . The procedure used for CHIP and germline variants calling

425 has been previously described 22,63 .

426 *MGBB*

Whole exome sequencing with an average coverage of $55 \times$ from whole blood DNA samples was performed for 13,356 MGBB participants. The procedure used for UKB CHIP calling (described above) was also applied for whole exome sequencing data in MGBB. Here, PON was created from 100 random whole exome sequencing samples from the youngest participants (age at enrolment $\leq 21y$). Putative CHIP mutations that passed the minimum depth of coverage (≥ 20) and supporting reads threshold were manually curated to arrive at the final CHIP call set.

433

434 Vanderbilt BioVU

Among 54,583 participants of the Vanderbilt BioVU, CHIP was identified in DNA genotyped on 435 the Illumina Multi-Ethnic Genotyping Array-Expanded (MEGAEX) for somatic mutations in four 436 known CHIP driver genes: DNMT3A, JAK2, TET2, and ASXL1. We examined nonsense, splice 437 site, and previously reported missense variants that are genotyped on the MEGA^{EX} array, totaling 438 439 29 CHIP mutations. B-allele fractions (BAF) were calculated from the intensity of alternate allele/ (alternate intensity + wild-type intensity), following the method previously developed and 440 validated by Hinds, et al. ⁴⁶. For validation of this method of detecting somatic mutations, we 441 evaluated 149 MEGA^{EX}-genotyped patients with a putative JAK2 mutation and performed NGS 442 analysis on the same DNA sample. The two genotyping methods demonstrated high concordance 443 down to the NGS limit of detection of 5% VAF (R²=0.9931). Because the MEGA^{EX}-sequenced 444 DNA samples were not available for DNMT3A, TET2, or ASXL1 at the time of the present study, 445 an alternative method was employed for these genes. The mean BAF and its standard deviation 446 were calculated for the population under 40 years of age. Detectable CHIP is extremely rare before 447 this age, allowing for the determination of the noise in BAF measurements at baseline. The BAFs 448 of the over-40 population were normalized to the under-40 mean and standard deviation. 449 Individuals with a normalized BAF greater than or equal to 6 standard deviations above the mean 450 were considered to have a somatic CHIP mutation. 451

452 **mCAs detection**

453 *UKB*

The detection of mCAs from genome-wide array genotyping of blood DNA in the UKB has been described in detail previously^{64,65}. Briefly, among 447,828 genotyped individuals in the UKB who passed sample quality control criteria, intensities from the genotyping arrays were used to yield

log₂R ratio and BAF for each SNP, and the Eagle2 software⁶⁶ was used to phase SNPs. mCAs
 calling was performed by leveraging long-range phase information to search for allelic imbalances

between maternal and paternal allelic fractions across contiguous genomic segments.
Constitutional duplications and low-quality calls were filtered out, and cell fraction was estimated
as previously described⁶⁵.

462

463 *MGBB*

The detection of mCAs in the MGBB was previously described³³. Briefly, among 22,143 464 participants who had available probe raw intensity data (IDAT) files for mCAs calling, genotype 465 clustering was performed using the Illumina GenCall algorithm, and the resulting GTC genotype 466 files were converted to VCF files using the bcftools gtc2vcf 467 plugin (https://github.com/freeseek/gtc2vcf). Genotype phasing was performed using SHAPEIT4⁶⁷, and 468 the phased genotypes were ligated across overlapping windows using beftools concat 469 (https://github.com/samtools/bcftools). mCAs detection in the MGBB was performed using 470 MoChA (https://github.com/freeseek/mocha), a workflow to process raw genotypes and probe 471 intensities to the final mCAs callset. Poor quality sample, defined as having a call rate below 0.97, 472 BAF auto-correlation across heterozygous sites greater than 0.03, likely germline calls, or runs of 473 homozygosity identified according to standard filtering practices described in the MoChA online 474

documentation, were excluded from further analysis.

476

477 Vanderbilt BioVU

A total of 51,028 participants in the Vanderbilt BioVU had their blood DNA genotyped on the
Illumina Multi-Ethnic Genotyping Array-Expanded (MEGA^{EX}). mCAs detection in BioVU was
then performed using MoChA (<u>https://github.com/freeseek/mocha</u>). Samples that did not pass
quality control criteria were excluded from the analysis.

482

483 Millions Veteran Program

484 DNA extracted from the whole blood of 613,329 participants in the Millions Veteran Program 485 (MVP) was genotyped using a customized Affymetrix Axiom Biobank array, the MVP 1.0 486 Genotyping Array, followed by standard QC and imputation as described elsewhere⁶⁸. mCAs were 487 detected using the MoChA pipeline (<u>https://github.com/freeseek/mocha</u>). Samples that did not 488 pass quality control criteria were excluded.

489

490 **GWAS and Meta-analysis**

491 GWAS for overall CHIP, *DNMT3A*, and *TET2* CHIP was performed using REGENIE⁶⁹ (in UKB,

- 492 MGB, and BioVU cohort) or SAIGE⁷⁰ (in TOPMed cohort, previously reported in Bick et al.²²).
- 493 We performed GWAS in UKB, MGBB, and BioVU cohorts separately with CHIP status (VAF≥2%

as "1", "0" otherwise) as the outcome, fitting a logistic mixed model, adjusting for age at enrolment, 494 age², sex, first ten principal components, self-reported ethnicity, and genotyping batch (where 495 appropriate). Here, only unrelated samples (one sample from each pair of 1st or 2nd-degree related 496 samples, or \geq 3rd-degree relatedness) with genotype missingness<10% and non-missing 497 498 outcome/covariates were included in the analysis. GWAS was performed in two steps: 1) prepare the null model using high-quality SNP in a leave-one-out cross-validation approach (REGENIE "-499 -loocy" flag), and 2) perform the single variant association. In Step 1, we used ~500k directly 500 genotyped SNP after excluding variants with minor allele frequency (MAF) below 5%, genotype 501 missingness above 10%, and Hardy-Weinberg equilibrium $P>1 \times 10^{-15}$. In Step 2, we used imputed 502 GWAS variants with a minor allele count >20 for the association test. To account for the case-503 control imbalance, we used the REGENIE "--firth" flag at GWAS P<0.01 to implement the Firth 504 likelihood test to control Type 1 errors. 505

Next, we meta-analyzed GWAS results from the four cohorts using inverse-variance weighted fixed-effect meta-analysis and Cochran's *Q*-test for heterogeneity in GWAMA software⁷¹. Here, variants at MAF \ge 0.1% and present in \ge 2 studies were included in the metaanalysis. Finally, variants were considered genome-wide significant at $P \le 1.67 \times 10^{-8}$, considering 1-million independent SNP and three outcomes tested at a 5% significance level (i.e., $5 \times 10^{-8}/3$).

511

512 Conditional and Joint Analysis (COJO)

Conditional and joint (COJO)^{72,73} analyses of summary statistics from multi-ancestry meta-513 analyses of CHIP, DNMT3A, and TET2 CHIP GWAS were performed using a multi-ancestry LD 514 reference prepared from the UKB imputed GWAS dataset that included all the 191k unrelated 515 samples used in our UKB CHIP GWAS. The LD panel included variants with MAF 20.1% and 516 INFO>0.3. In the COJO analyses, we conditioned the lead variant (false discovery rate (FDR) 517 <5%) from each chromosome, and independent variants (FDR <5% and LD with the conditioned 518 variant<0.8) were included iteratively. Finally, all variants were fitted simultaneously in the joint 519 analyses when multiple independent variants were detected in the same chromosome. Independent 520 variants at $P \le 1.67 \times 10^{-8}$ were considered genome-wide significant. 521

522 **SNP-based heritability** (h^2 *_{SNP}*)

We estimated h_{SNP}^2 using the summary statistics from the multi-ancestry meta-analysis of CHIP 523 GWAS. We used the SumHer function of LDAK software^{74,75} with precomputed LD tagging 524 https://genetics.ghpc.au.dk/doug/bld.ldak.genotyped.gbr.tagging.gz) 525 (BLD-LDAK model: prepared from directly genotyped UKB EUR sample. The BLD-LDAK EUR LD tagging was 526 527 prepared using 577,457 non-ambiguous directly genotyped SNP from 2,000 white British 528 individuals. Using 573,701 overlapping SNP from the summary statistics, h^{2}_{SNP} was estimated on a liability scale assuming a sample and population CHIP prevalence of 5%. 529

530 MashR

To nominate potentially associated variants, we leveraged the observation that myeloproliferative 531 neoplasm (MPN) shared strong germline genetic susceptibility with CHIP³⁰. We used MPN 532 GWAS summary statistics from Bao, et al. ³⁰, and applied mashR (Multivariate Adaptive 533 Shrinkage in R)³⁴ to 6,749,139 variants across MPN, CHIP, DNMT3A, and TET2 using the 534 exchangeable Z statistic model. Briefly, we fit the empirical Bayes prior by using the maximum 535 SNP across each of the 1,703 linkage disequilibrium (LD) blocks specified in Pickrell, et al. ⁷⁶ and 536 used a random sampling of 40,000 SNPs to estimate the relative abundance of each pattern in the 537 overall data set. Armed with this prior information, we then estimated the likelihood and computed 538 posteriors on all variants. 539

540

541 Statistical fine-mapping

To infer putative causal variants in the associated loci, we conducted LD-informed statistical finemapping. We derived the LD-matrix of tested variants in each locus using UK Biobank imputed dosage of European ancestries by LDstore2 software (version 2.0)⁷⁷. Using derived LD-matrices, we applied statistical fine-mapping using the summary statistics obtained from the European metaanalysis (only included GWAS of EUR samples from UKB, TOPMed, MGBB, BioVU) by FINEMAP software (version 1.4)²⁴. To obtain consistent statistical power for each variant, we only kept variants tested in at least 200,000 individuals.

549

550 Similarity-based gene polygenic prioritization of causal genes

551 We implemented PoPS to leverage the full genome-wide signal for nominating causal genes. Details of these methods have been described elsewhere²⁵. Briefly, PoPS is a novel similarity-552 based gene prioritization approach that assesses the polygenic enrichments of gene features, 553 including cell-type-specific gene expression, protein-protein interaction networks, and biological 554 pathways, through training linear models to predict gene-level association scores from those 555 features and converting the gene p-values from the linear models to Z-scores that reflect the 556 confidence on its causal role to the given locus. We used the summary statistics of UKB CHIP, 557 DNMT3A, and TET2 GWAS and the same LD reference panel of 191k UKB samples used in 558 COJO analysis. In total, 57,543 features were considered for analysis, and those who passed 559 560 marginal feature selection were carried forward to the linear models for computation. We computed a PoPS score for all protein-coding genes within a defined 500kb window around each 561 of the significant genomic regions and prioritized the gene with the highest PoPS score in each 562 locus. 563

565 Mendelian randomization

All procedures for the MR analysis between CHIP and CAD were consistent with current 566 recommendations for MR studies⁷⁸. IVs detected in European-only CHIP GWAS were used for 567 this causal analysis. While genetic predispositions for CHIP overlap with those for LTL, previous 568 MR studies support inverse causality for LTL on CAD⁷⁹, implying complex causal relationships 569 between CHIP, LTL, and CAD²³. Thus, we carefully selected instrumental variables (IVs) to avoid 570 clear violations of MR assumptions by excluding IVs 1) associated with known confounders 571 between CHIP and CAD, including hypercholesterolemia, hypertension, type 2 diabetes, body 572 mass index, smoking status, or 2) having more robust associations with LTL than with CAD, and 573 3) having inverse effect sizes for LTL and CAD, accounting for the inverse causal association 574 between LTL We used CAD GWAS and CAD. summary statistics from 575 CARDIOGRAMplusC4D⁸⁰ for the outcome (last accessed March 2022; downloaded from: 576 http://www.cardiogramplusc4d.org/). We downloaded summary statistics from OpenGWAS 577 project^{81,82} for excluding IVs which strongly ($P < 5 \times 10^{-8}$) associated with known confounders 578 between CHIP and CAD, including hypercholesterolemia (ukb-b-12651), hypertension (ukb-d-579 19 HYPTENS), type 2 diabetes (ebi-a-GCST007518), body mass index (ukb-b-2303), smoking 580 status (ukb-b-20261). We used the full summary statistics for LTL GWAS from the previous study 581 in UKB to inspect the association with LTL⁷⁹. Since we do not have many SNPs that pass through 582 the genome-wide significance, particularly for TET2, we used the multi-ancestry meta-analysis of 583 DNMT3A and TET2 CHIP summary statistics and MR using the robust adjusted profile score (MR-584 RAPS), which allows for the inclusion of weak IVs⁴², as the primary method. We performed 585 sensitivity analyses using inverse-variance weighted (IVW)⁸³, weighted median⁸³, weighted 586 mode⁸⁴, MR-Egger⁸⁵, and MR-PRESSO⁸⁶ methods available in the TwoSampleMR⁸² package in 587 R. For all MR methods except for MR-RAPS, genome-wide significance ($P < 5 \times 10^{-8}$) was 588 considered as the criteria for the IV assumption of robust relevance (the first assumption of MR). 589 We relaxed this assumption for MR-RAPs to $P < 1 \times 10^{-3}$, 1×10^{-4} , and 1×10^{-5} . IVs were clumped into 590 independent loci<10 Mb apart and in the linkage equilibrium (R²>0.001 calculated in European 591 ancestry in UKB) using PLINK (v1.90b6.24)⁸⁷. Due to the limited availability of CHIP GWAS to 592 date, we could not use an independent cohort for IV discovery for MR-RAPS and Steiger filtering 593 594 to avoid the potential "winner's curse".

595

596 **PheWAS analysis**

597 The PheWAS of CHIP and mCAs with incident phenotypes across all disease organ system 598 categories were performed using Cox proportional hazards models, adjusting for age, age², sex 599 (not used for ChrY and ChrX mCAs analysis), smoking status (using a 25-factor smoking status 600 adjustment in the UKB and current/prior/never smoker status in other cohorts), tobacco use 601 disorder, and principal components 1-10 of genetic ancestry. The primary comparative analysis 602 was conducted among individuals from UKB who had both CHIP and mCAs calls available.

Additionally, in the secondary analysis, mCAs associations were meta-analyzed across the multi-603 ancestry study population of UKB, MGBB, BioVU, and MVP. Time since DNA collection was 604 used as the underlying timescale. The proportional hazards assumption was assessed using 605 Schoenfeld residuals and was not rejected. Individuals with a history of hematological cancer 606 607 before DNA collection were excluded. To address multiple testing, an association between CHIP or mCAs and incident health outcomes with FDR<0.05 was considered significant. Analyses of 608 incident events were performed separately in each biobank using the survival package in R (version 609 3.5, R Foundation). Meta-analyses of the mCAs results were performed using a fixed-effects 610 model from the "meta" R package. 611

612

613 CHIP associations at the cell-type level

614 scDRS group analysis was used to assess the polygenic associations of CHIP, DNMT3A, and TET2 at cell type and tissue level. Details of the methods have been described elsewhere³¹. Briefly, 615 scDRS is a novel statistical method that associates individual cells in a scRNA-seq data to a trait 616 617 GWAS based on the aggregate expression across a set of putative GWAS trait genes, assessing 618 statistical significance using appropriately matched control genes; furthermore, the scDRS group analysis computes a p-value for a cell group (e.g., cell type or tissue) based on the association of 619 cells within the given cell group. Following the scDRS guideline, the putative trait gene sets were 620 constructed as the top 1,000 MAGMA genes, where MAGMA⁸⁸, an existing gene-scoring method, 621 was applied to GWASs from UKB participants of European ancestry using a set of 489 unrelated 622 individuals of European ancestry from phase 3 1000 Genomes Project as an LD reference panel⁸⁹. 623 Two scRNA-seq data sets were used for this analysis: TMS mouse cell atlas⁴⁴ (FACS data with 624 110,824 cells, 23 tissues, and 103 cell types with more than 50 cells) and TS human cell atlas⁴⁵ 625 (FACS data with 26,813 cells, 24 tissues, and 68 cell types with more than 50 cells). Multiple 626 testing correlation (FDR) was applied to each trait separately across all cell types (103 for TMS 627 and 68 for TS) or across all tissues (23 for TMS and 24 for TS). To increase power, associations 628 were considered significant at FDR<0.3, and all suggestive associations with P<0.01 were reported. 629 Sensitivity analyses were conducted by repeating the analysis using downsampled scRNA-seq data 630 (to 50K cells) and downsampled putative trait gene sets (to 500 genes) separately, each with 20 631 repetitions. 632

Data availability 634

- All univariable summary statistics for genotype association with CHIP will be available at the time 635
- of publication. Epigenome annotation tracks: We obtained chromHMM100 tracks from diverse 636
- primary human cells from the NIH Epigenome Roadmap (http://dcc.blueprint-637 and
- epigenome.eu/#/md/secondary analysis/Segmentation of ChIP-Seq data 20140811), 638
- additional immune-specific human primary and cell lines from the Blueprint consortium, 639
- https://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/core 640
- Marks/jointModel/final. Whole-blood eQTL summary statistics: Summary statistics from whole-641
- blood cis-eQTL analysis from 31,683 individuals were downloaded from https://eqtlgen.org. Code 642
- used to generate all data in main and supplemental tables and figures will be provided in a publicly 643 accessible archive at the time of publication. 644

645 Acknowledgments

We thank the investigators and their studies for contributing samples and/or data to the current 646 work and the participants in those studies who made this research possible. This research has been 647 conducted using the UK Biobank Resource under Application Number 7089 and 50834. This 648 research is based on data from the Vanderbilt BioVU, which is supported by NIH Grant UL1 649 RR024975-01and UL1 TR000445-06. This research is also based on data from the Million Veteran 650 Program, Office of Research and Development, Veterans Health Administration, and was 651 supported by Million Veteran Program-MVP000. This publication does not represent the views of 652 the Department of Veteran Affairs or the United States Government. 653

Fundings 654

Z.Y. is supported by a grant from NHLBI (5T32HL007604-37). A.G.B. is supported by a Burroughs 655 Wellcome Foundation Career Award for Medical Scientists and the NIH Director's Early Independence 656 Award (DP5-OD029586). A.J.S. is supported by NIH grant F30-DK127699. A.J.S., M.A.R., and H.A.K. 657 are supported by NIH grant T32-GM007347. A.N. is supported by Knut and Alice Wallenberg Foundation 658 (KAW 2017.0436). A.P.R. is supported by NIH grants R01 HL148565 and R01 HL146500. B.L.E. is 659 supported by Leducq Foundation. G.G. is supported by NIH grants R01 MH104964 and R01 MH123451, 660 661 and Stanley Center for Psychiatric Research. K.C., Y.V.S., and P.W.F.W are supported by Million Veteran 662 Program (MVP) grant numbers I01-BX003340 and I01-BX004821. K.P. is supported by grants from the NHLBI (5-T32HL007208-43). M.C.H. is supported by the American Heart Association (940166 and 663 979465). P.N. is supported by grants from the NHLBI (R01HL142711, R01HL127564, R01HL148050, 664 R01HL151283, R01HL148565, R01HL135242, R01HL151152), National Institute of Diabetes and 665 Digestive and Kidney Diseases (R01DK125782), Fondation Leducg (TNE-18CVD04), and Massachusetts 666 667 General Hospital (Paul and Phyllis Fireman Endowed Chair in Vascular Medicine). P.T.E. is supported by 668 the National Institutes of Health (1RO1HL092577), the American Heart Association Strategically Focused Research Networks (18SFRN34110082), and the European Union (MAESTRIA 965286). S.J. is supported 669 670 by the Burroughs Wellcome Fund Career Award for Medical Scientists, Fondation Leducq (TNE-671 18CVD04), the Ludwig Center for Cancer Stem Cell Research at Stanford University, and the National

Institutes of Health (DP2-HL157540). T.M.M. is supported by NIH grant T32-HL144446. V.G.S. is
supported by NIH grants R01 DK103794 and R01 HL146500.

674

675 Author Contributions

A.G.B. and P.N. designed and conceived the study. A.G.B. and P.N. supervised the study. M.M.U.,
Z.Y., J.S.W., T.N., A.N., S.M.U., S.K., S.M.Z., K.P., A.J.S., T.M.M., M.Y.W., S.M.H., R.B.,
S.D.J., M.R., M.C.H., W.E.H., M.J.Z., V.G.S., G.K.G., C.J.G., H.A.K., P.T.E., K.C., Y.S., P.W.,
S.P., G.G., Y.X., M.R.S., A.P.R, S.J., B.L.E., A.G.B., and P.N. acquired, analyzed or interpreted
the data. M.M.U., Z.Y., T.N., S.M.U., S.K., S.M.Z, A.B., and P.N. drafted the manuscript. All
authors critically reviewed the manuscript.

682

683 **Competing Interests**

All unrelated to the present work: A.G.B. is a scientific co-founder and has equity in TenSixteen 684 Bio. B.L.E. has received research funding from Celgene, Deerfield, Novartis, and Calico and 685 consulting fees from GRAIL. B.L.E is a member of the scientific advisory board and shareholder 686 for Neomorph Therapeutics, TenSixteen Bio, Skyhawk Therapeutics, and Exo Therapeutics. 687 M.C.H. has received consulting fees from CRISPR Therapeutics and is on the medical advisory 688 board of Miga Health. P.N. reports grant support from Amgen, Apple, AstraZeneca, Novartis, and 689 Boston Scientific, consulting income from Apple, AstraZeneca, Blackstone Life Sciences, 690 Genentech, and Novartis, and spousal employment at Vertex, all unrelated to the present work. 691 P.N., A.G.B, S.J., and B.E. are scientific advisors with equity in TenSixteen Bio, which had no 692 role in the present work. P.T.E. receives sponsored research support from Bayer AG and IBM 693 Research; he has also served on advisory boards or consulted for Bayer AG, MyoKardia, and 694 695 Novartis. S.J. is a consultant to Novartis, Roche Genentech, AVRO Bio, and Foresite Labs, and on the scientific advisory board for Bitterroot Bio, founder and equity holder of TenSixteen Bio. 696 V.G.S. serves as an advisor to and/or has equity in Branch Biosciences, Ensoma, Novartis, Forma, 697 Sana Biotechnology, and Cellarity. All other authors declare that they have no competing interests. 698

700	References				
701					
702 703	1.	Xie, M. <i>et al.</i> Age-related mutations associated with clonal hematopoietic expansion and malignancies. <i>Nat Med</i> 20 , 1472-8 (2014).			
704 705	2.	Genovese, G. <i>et al.</i> Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. <i>N Engl J Med</i> 371 , 2477-87 (2014).			
706 707	3.	Jaiswal, S. <i>et al.</i> Age-related clonal hematopoiesis associated with adverse outcomes. <i>N Engl J</i> <i>Med</i> 371 , 2488-98 (2014).			
708 709	4.	Delhommeau, F. <i>et al.</i> Mutation in TET2 in myeloid cancers. <i>N Engl J Med</i> 360 , 2289-301 (2009).			
710 711	5.	Ley, T.J. <i>et al.</i> DNMT3A mutations in acute myeloid leukemia. <i>N Engl J Med</i> 363 , 2424-33 (2010).			
712 713 714	6.	Je, E.M., Yoo, N.J., Kim, Y.J., Kim, M.S. & Lee, S.H. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. <i>Int J Cancer</i> 133 , 260-5 (2013).			
715 716	7.	Abdel-Wahab, O. <i>et al.</i> ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. <i>Cancer Cell</i> 22 , 180-93 (2012).			
717 718 710	8.	Coombs, C.C. <i>et al.</i> Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. <i>Cell Stem Cell</i> 21 , 374-382 c4 (2017)			
719 720 721	9.	Xia, J. <i>et al.</i> Somatic mutations and clonal hematopoiesis in congenital neutropenia. <i>Blood</i> 131 , 408-416 (2018).			
722 723	10.	Hsu, J.I. <i>et al.</i> PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. <i>Cell Stem Cell</i> 23 , 700-713 e6 (2018).			
724 725	11.	Steensma, D.P. <i>et al.</i> Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <i>Blood</i> 126 , 9-16 (2015).			
726 727	12.	Abelson, S. <i>et al.</i> Prediction of acute myeloid leukaemia risk in healthy individuals. <i>Nature</i> 559 , 400-404 (2018)			
728 729	13.	Desai, P. <i>et al.</i> Somatic mutations precede acute myeloid leukemia years before diagnosis. <i>Nat</i> <i>Med</i> 24, 1015-1023 (2018).			
730 731	14.	Jaiswal, S. <i>et al.</i> Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. <i>N</i> <i>Engl J Med</i> 377 , 111-121 (2017).			
732 733	15.	Bick, A.G. <i>et al.</i> Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis. <i>Circulation</i> 141 , 124-131 (2020).			
734 735	16.	Bhattacharya, R. <i>et al.</i> Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. <i>Stroke</i> 53 , 788-797 (2022).			
736 737	17.	Yu, B. <i>et al.</i> Association of Clonal Hematopoiesis With Incident Heart Failure. <i>J Am Coll Cardiol</i> 78 , 42-52 (2021).			
738 739	18.	Miller, P.G. <i>et al.</i> Association of clonal hematopoiesis with chronic obstructive pulmonary disease. <i>Blood</i> 139 , 357-368 (2022).			
740 741	19.	Kim, P.G. <i>et al.</i> Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. <i>J Exp Med</i> 218 (2021).			

742	20.	Wong, W.J. et al. Clonal hematopoiesis and risk of chronic liver disease. medRxiv,
743		2022.01.17.22269409 (2022).
744	21.	Bouzid, H. et al. Clonal hematopoiesis is associated with protection from Alzheimer's disease.
745		medRxiv, 2021.12.10.21267552 (2021).
746	22.	Bick, A.G. et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature
747		586 , 763-768 (2020).
748	23.	Nakao, T. et al. Mendelian randomization supports bidirectional causality between telomere
749		length and clonal hematopoiesis of indeterminate potential. Sci Adv 8, eabl6579 (2022).
750	24.	Benner, C. et al. FINEMAP: efficient variable selection using summary data from genome-wide
751		association studies. Bioinformatics 32, 1493-501 (2016).
752	25.	Weeks, E.M. et al. Leveraging polygenic enrichments of gene features to predict genes
753		underlying complex traits and diseases. medRxiv, 2020.09.08.20190561 (2020).
754	26.	Ciccia, A. & Elledge, S.J. The DNA damage response: making it safe to play with knives. Mol
755		<i>Cell</i> 40 , 179-204 (2010).
756	27.	Huang, R.X. & Zhou, P.K. DNA damage response signaling pathways and targets for
757		radiotherapy sensitization in cancer. Signal Transduct Target Ther 5, 60 (2020).
758	28.	Mencia-Trinchant, N. et al. Clonal Hematopoiesis Before, During, and After Human Spaceflight.
759		<i>Cell Rep</i> 33 , 108458 (2020).
760	29.	Jasra, S. et al. High burden of clonal hematopoiesis in first responders exposed to the World
761		Trade Center disaster. Nat Med 28, 468-471 (2022).
762	30.	Bao, E.L. et al. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells.
763		Nature 586, 769-775 (2020).
764	31.	Zhang, M.J. et al. Polygenic enrichment distinguishes disease associations of individual cells in
765		single-cell RNA-seq data. bioRxiv, 2021.09.24.461597 (2021).
766	32.	Codd, V. et al. Polygenic basis and biomedical consequences of telomere length variation. Nat
767		Genet 53, 1425-1433 (2021).
768	33.	Zekavat, S.M. et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse
769		types of infection. Nat Med 27, 1012-1024 (2021).
770	34.	Urbut, S.M., Wang, G., Carbonetto, P. & Stephens, M. Flexible statistical methods for estimating
771		and testing effects in genomic studies with multiple conditions. Nat Genet 51, 187-195 (2019).
772	35.	Helgason, H. et al. Loss-of-function variants in ATM confer risk of gastric cancer. Nat Genet 47,
773		906-10 (2015).
774	36.	Karantanos, T. et al. ATM Germline Variant Increases the Risk of MPN Progression. Blood 134,
775		835-835 (2019).
776	37.	Li, X. et al. High PARP-1 expression predicts poor survival in acute myeloid leukemia and
777		PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment
778		synergistically enhances anti-tumor effects. EBioMedicine 38, 47-56 (2018).
779	38.	Min, J.L. et al. Genomic and phenotypic insights from an atlas of genetic effects on DNA
780		methylation. Nat Genet 53, 1311-1321 (2021).
781	39.	Weinstock, J.S. et al. Clonal hematopoiesis is driven by aberrant activation of TCL1A. bioRxiv,
782		2021.12.10.471810 (2021).
783	40.	Fuster, J.J. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates
784		atherosclerosis development in mice. Science 355, 842-847 (2017).

785 41. Wang, Y. et al. Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-786 associated cardiac dysfunction. JCI Insight 5(2020). Zhao, Q., Wang, J., Hemani, G., Bowden, J. & Small, D.S. Statistical inference in two-sample 787 42. 788 summary-data Mendelian randomization using robust adjusted profile score. The Annals of 789 Statistics 48, 1742-1769, 28 (2020). 790 43. Niroula, A. et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med 27, 1921-791 1927 (2021). 792 44. Tabula Muris, C. A single-cell transcriptomic atlas characterizes ageing tissues in the mouse. 793 Nature 583, 590-595 (2020). Consortium, T.T.S. & Quake, S.R. The Tabula Sapiens: a multiple organ single cell 794 45. 795 transcriptomic atlas of humans. bioRxiv, 2021.07.19.452956 (2021). 796 Hinds, D.A. et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and 46. 797 myeloproliferative neoplasms. Blood 128, 1121-8 (2016). Shiloh, Y. & Ziv, Y. The ATM protein kinase: regulating the cellular response to genotoxic 798 47. stress, and more. Nat Rev Mol Cell Biol 14, 197-210 (2013). 799 800 48. Krishnakumar, R. & Kraus, W.L. The PARP side of the nucleus: molecular actions, physiological 801 outcomes, and clinical targets. Mol Cell 39, 8-24 (2010). 802 49. Virgilio, L. et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl 803 *Acad Sci U S A* **91**, 12530-4 (1994). Said, J.W. et al. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and 804 50. distinct classes of B cell lymphoma. Lab Invest 81, 555-64 (2001). 805 Pekarsky, Y. et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc 806 51. Natl Acad Sci US A 97, 3028-33 (2000). 807 808 52. Laine, J., Kunstle, G., Obata, T., Sha, M. & Noguchi, M. The protooncogene TCL1 is an Akt 809 kinase coactivator. Mol Cell 6, 395-407 (2000). Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 810 53. 811 562, 203-209 (2018). 812 54. Nachun, D. et al. Clonal hematopoiesis associated with epigenetic aging and clinical outcomes. 813 Aging Cell 20, e13366 (2021). 814 55. Karlson, E.W., Boutin, N.T., Hoffnagle, A.G. & Allen, N.L. Building the Partners HealthCare Biobank at Partners Personalized Medicine: Informed Consent, Return of Research Results, 815 816 Recruitment Lessons and Operational Considerations. J Pers Med 6(2016). 817 56. Danciu, I. et al. Secondary use of clinical data: the Vanderbilt approach. J Biomed Inform 52, 28-818 35 (2014). 819 Roden, D.M. et al. Development of a large-scale de-identified DNA biobank to enable 57. 820 personalized medicine. Clin Pharmacol Ther 84, 362-9 (2008). 821 Benjamin, D. et al. Calling Somatic SNVs and Indels with Mutect2. bioRxiv, 861054 (2019). 58. 822 59. Karczewski, K.J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434-443 (2020). 823 824 Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from 60. 825 high-throughput sequencing data. Nucleic Acids Res 38, e164 (2010). 826 61. Regier, A.A. et al. Functional equivalence of genome sequencing analysis pipelines enables 827 harmonized variant calling across human genetics projects. Nat Commun 9, 4038 (2018).

828	62.	Jun, G., Wing, M.K., Abecasis, G.R. & Kang, H.M. An efficient and scalable analysis framework
829		for variant extraction and refinement from population-scale DNA sequence data. Genome Res 25,
830		918-25 (2015).
831	63.	Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
832		<i>Nature</i> 590 , 290-299 (2021).
833	64.	Loh, P.R., Genovese, G. & McCarroll, S.A. Monogenic and polygenic inheritance become
834		instruments for clonal selection. Nature (2020).
835	65.	Loh, P.R. et al. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations.
836		<i>Nature</i> (2018).
837	66.	Loh, P.R. et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat
838		<i>Genet</i> 48 , 1443-1448 (2016).
839	67.	Delaneau, O., Zagury, J.F., Robinson, M.R., Marchini, J.L. & Dermitzakis, E.T. Accurate,
840		scalable and integrative haplotype estimation. Nat Commun 10, 5436 (2019).
841	68.	Klarin, D. et al. Genome-wide association study of peripheral artery disease in the Million
842		Veteran Program. Nat Med 25, 1274-1279 (2019).
843	69.	Mbatchou, J. et al. Computationally efficient whole-genome regression for quantitative and
844		binary traits. Nat Genet 53, 1097-1103 (2021).
845	70.	Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in large-
846		scale genetic association studies. Nat Genet 50, 1335-1341 (2018).
847	71.	Magi, R. & Morris, A.P. GWAMA: software for genome-wide association meta-analysis. BMC
848		<i>Bioinformatics</i> 11, 288 (2010).
849	72.	Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics
850		identifies additional variants influencing complex traits. Nat Genet 44, 369-75, S1-3 (2012).
851	73.	Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide complex
852		trait analysis. Am J Hum Genet 88, 76-82 (2011).
853	74.	Speed, D. & Balding, D.J. SumHer better estimates the SNP heritability of complex traits from
854		summary statistics. Nat Genet 51, 277-284 (2019).
855	75.	Speed, D., Holmes, J. & Balding, D.J. Evaluating and improving heritability models using
856		summary statistics. Nat Genet 52, 458-462 (2020).
857	76.	Pickrell, J.K. et al. Detection and interpretation of shared genetic influences on 42 human traits.
858		Nat Genet 48, 709-17 (2016).
859	77.	Benner, C. et al. Prospects of Fine-Mapping Trait-Associated Genomic Regions by Using
860		Summary Statistics from Genome-wide Association Studies. Am J Hum Genet 101, 539-551
861		(2017).
862	78.	Burgess, S. et al. Guidelines for performing Mendelian randomization investigations. Wellcome
863		<i>Open Res</i> 4 , 186 (2019).
864	79.	Codd, V. et al. Identification of seven loci affecting mean telomere length and their association
865		with disease. Nat Genet 45, 422-7, 427e1-2 (2013).
866	80.	Nikpay, M. et al. A comprehensive 1,000 Genomes-based genome-wide association meta-
867		analysis of coronary artery disease. Nat Genet 47, 1121-1130 (2015).
868	81.	Elsworth, B. et al. The MRC IEU OpenGWAS data infrastructure. bioRxiv, 2020.08.10.244293
869		(2020).
870	82.	Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human
871		phenome. <i>Elife</i> 7 (2018).

872	83.	Bowden, J., Davey Smith, G., Haycock, P.C. & Burgess, S. Consistent Estimation in Mendelian				
873		Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet				
874		<i>Epidemiol</i> 40 , 304-14 (2016).				
875	84.	Burgess, S., Foley, C.N., Allara, E., Staley, J.R. & Howson, J.M.M. A robust and efficient				
876		method for Mendelian randomization with hundreds of genetic variants. Nat Commun 11, 376				
877		(2020).				
878	85.	Burgess, S. & Thompson, S.G. Interpreting findings from Mendelian randomization using the				
879		MR-Egger method. Eur J Epidemiol 32, 377-389 (2017).				
880	86.	Verbanck, M., Chen, C.Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in				
881		causal relationships inferred from Mendelian randomization between complex traits and diseases.				
882		Nat Genet 50, 693-698 (2018).				
883	87.	Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage				
884		analyses. Am J Hum Genet 81, 559-75 (2007).				
885	88.	de Leeuw, C.A., Mooij, J.M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set				
886		analysis of GWAS data. PLoS Comput Biol 11, e1004219 (2015).				
887	89.	Genomes Project, C. et al. A global reference for human genetic variation. Nature 526, 68-74				
888		(2015).				

) Figures



L

)

Fig. 1 | **Identifying CHIP in 300,600 whole-genome or whole-exome samples. a**, CHIP prevalence increased with the age of the donor at the time of blood sampling. The centre line represents the general additive model spline, and the shaded region is the 95% confidence interval (N_{UKB}=200,128 WES; N_{TOPMed}=87,116 WGS; N_{MGBB}=13,356 WES). **b**, More than 90% of individuals with CHIP had only one somatic CHIP driver mutation variant identified. **c**, Proportion of individuals carrying a driver mutation in the ten most frequently mutated genes in CHIP. **d**, There was heterogeneity in CHIP clone size as measured by variant allele fraction by CHIP driver gene. Violin plot spanning minimum and maximum values with median variant allele fraction highlighted by white circles. Information on BioVU was not included as CHIP call is array-based. CHIP: clonal hematopoiesis of indeterminate potential; WES: whole-exome samples; WGS: whole-genome samples.

- ł



Fig. 2 | **Genetic determinants of** *CHIP*, *DNMT3A*, and *TET2*. Gnome-wide meta-analyses of CHIP identified (**a**) ten genome-wide-significant (P<1.67e-8) regions for overall CHIP (n=17,044 cases and n=306,068 controls), (b) ten for *DNMT3A* CHIP (n=8,949 cases and n=307,971 controls), and (**c**) six for *TET2* CHIP (n=2,851 cases and n=307,527 controls). Previously known loci in blue, and new loci in red. **d**, Overlap of significant variants from (**a**-**c**) with GWAS of myeloproliferative neoplasm (MPN)³⁰, leukocyte telomere length (LTL)³², and expanded mosaic chromosomal alterations (mCAs)³³. Only genome-wide significant (P<5e-8) variants from MPN, LTL, and expanded mCAs GWAS were considered to compare the overlap with variants from overall CHIP, *DNMT3A*, and *TET2* CHIP GWAS (P<1.67e-8). CHIP: clonal hematopoiesis of indeterminate potential.

3

7 3

))

L





5 7

3

)

)

L

Fig. 3 | **Statistical fine mapping in the genome-wide significant loci. a**, Regional association plot for *ATM* locus. X-axis shows genetic coordinate. Y-axes show -log10 P-value and PPI. **b**, In-silico functional prediction for putative causal missense variant rs1800057 (ENST00000675843.1:c.3161C>G:p.Pro1054Arg) in *ATM* gene. **c**, Regional association plot for *PARP1* locus. **d**, *PARP1* expression in human whole blood by genotypes at rs1527365 (https://gtexportal.org/). The effect allele rs1527365-T is associated with lower expression of *PARP1*. NES: normalized effect size.

<u>2</u> 3

Study	IV	Threshold	d	β	SE	Р
Any CHIP	258	1 × 10 ⁻³		0.016	0.013	0.23
	141	1 × 10 ⁻⁴	⊦	0.013	0.017	0.45
	32	1 × 10 ⁻⁵	⊦{	-0.0029	0.028	0.92
	7	5 × 10 ⁻⁸	+I	-0.043	0.045	0.34
DNMT3A	237	1 × 10 ⁻³		0.0059	0.011	0.59
	132	1 × 10 ⁻⁴	+	0.00098	0.013	0.94
	40	1 × 10 ⁻⁵	⊨	-0.012	0.02	0.53
	6	5 × 10 ⁻⁸	+ ■	-0.034	0.032	0.29
TET2	202	1 × 10 ⁻³	+ -■ - 1	0.023	0.0071	0.0013
	120	1 × 10 ⁻⁴	⊢ - ■	0.031	0.0087	0.00032
	24	1 × 10 ⁻⁵	■	0.024	0.017	0.16
	0	5 × 10 ⁻⁸				
			-0.125 -0.1 -0.075 -0.05 -0.025 0 0.025 0.05 0.075	i		

5 Figure 4. Mendelian randomization for CHIP and CAD using MR-RAPS. MR-RAPS for CHIP and CAD including weak IVs. We 5 selected IVs using GWAS summary statistics for any CHIP, DNMT3A, and TET2, and filtered out the IVs with 1) associated with known 7 confounders between CHIP and CAD, including hypercholesterolemia, hypertension, type 2 diabetes, body mass index, smoking status, 3 or 2) having more robust associations with LTL than with CAD, and 3) having inverse effect sizes for LTL and CAD, accounting for the) inverse causal association between LTL and CAD.1) more robust association with LTL than CAD, and 2) the opposite directionality of) the effect for LTL and CAD, to avoid potential confounding by LTL. We used CAD GWAS summary statistics from CARDIOGRAMplusC4D for outcome. CAD: coronary artery disease, CHIP: clonal hematopoiesis of indeterminate potential, IV: L 2 instrumental variable, LTL: leukocyte telomere length, SE: standard error.

3



Figure 5: Heat map of significant associations between CHIP or mCAs and incident conditions from phenome-wide association analysis: (a) Hematopoietic conditions and
 neoplasms and (b) Non-hematopoietic/neoplastic conditions. PheCode phenotypes were filtered to those with CHIP or mCA FDR<0.05 among incident phenotypes with at least
 5 incident cases. The CHIP and mCA analyses were conducted among the same subset of individuals in the UK Biobank with both CHIP and mCA calls available. All analyses were
 adjusted for age, age², sex (not used for ChrY and Chr X mCA analysis), smoking status (using a 25-factor smoking status adjustment in the UK Biobank and current/prior/never
 smoker status in other cohorts), tobacco use disorder, and principal components 1-10 of genetic ancestry. Colors in heat map reflect z-score (beta/se) of associations. * denotes
 0.01≤FDR≤0.05, ** denotes 0.0001<FDR<0.01, *** denotes FDR<0.0001. CHIP: clonal hematopoiesis of indeterminate potential, mCAs: mosaic chromosomal alterations.



2

L

- Figure 6: Cell type-level associations in TMS. Cell type-level associations in TMS. The x-axis represents scDRS –log10 cell type-
- level association p-values while the y-axis represents potentially associated cell types (P<0.01) for the 3 traits, ordered by significance.
 * denotes FDR<0.3, ** denotes FDR<0.2, and *** denotes FDR<0.1 across all cell types for a given trait. CHIP: clonal hematopoiesis
- of indeterminate potential. TMS: Tabula Muris Senis.